What Are the Common Side Effects of TRT?
Most men on testosterone replacement therapy experience mild, manageable side effects — or none at all. The most common issues include acne and oily skin, breast tissue growth (gynecomastia), elevated red blood cell counts (erythrocytosis), fluid retention, testicular shrinkage, and reduced sperm production.1 Serious complications are rare when you follow a proper monitoring schedule.
The key is baseline screening and routine bloodwork. Your clinician checks hematocrit at 3-6 months and annually, pauses treatment if levels exceed 54%, and monitors PSA to catch prostate changes early.2 Most side effects resolve with dose adjustments or formulation changes.
This guide covers what you're likely to experience, what the research shows about serious risks, and how monitoring prevents complications before they escalate.
Learn More About TRT
Related Guides: TRT Basics, TRT Benefits and Results Timeline, TRT and Prostate Cancer Concerns, TRT and Cardiovascular Health
Conditions to Understand: Gynecomastia Management, Erythrocytosis on TRT, Sleep Apnea and Testosterone, Male Infertility and Fertility Preservation
Next Step: Schedule an initial TRT assessment to discuss your individual risk factors, baseline labs, and monitoring schedule. Your clinician will screen for contraindications and build a protocol that minimizes side effects.
Monitoring Services: Ongoing lab tracking, hematocrit management, PSA monitoring, and dose adjustments to keep side effects minimal and benefits maximized.
Mild and Moderate Side Effects You May Experience
Acne and oily skin show up within weeks for some men. Your sebaceous glands ramp up production as testosterone levels rise. The breakouts typically appear on your back, shoulders, and face.
Most cases clear up within a few months as your body adjusts. Switching from injections to a gel or cream sometimes helps. Topical treatments or a temporary dose reduction usually resolves stubborn acne.
Gynecomastia — breast tissue growth behind the nipple — affects a subset of users. Testosterone converts to estrogen through an enzyme called aromatase. If estrogen climbs too high relative to testosterone, breast tissue develops.
Early gynecomastia feels like a small, tender lump. Catching it at this stage matters. Adjusting your dose or adding an aromatase inhibitor stops progression. Established breast tissue requires surgical removal.
Fluid retention causes puffiness in your face, hands, and ankles. You might gain 3-7 pounds of water weight in the first month. The effect is temporary for most men and resolves as your body equilibrates.
Testicular shrinkage happens because exogenous testosterone suppresses luteinizing hormone (LH). Without LH signaling, your testes stop producing testosterone and shrink.3 The change is reversible if you stop therapy. Adding human chorionic gonadotropin (HCG) during treatment preserves testicular size and function.
Reduced sperm production is nearly universal. TRT shuts down the hormonal pathway that drives sperm creation. Your sperm count drops significantly, and fertility declines. Recovery takes months after stopping treatment. If you're planning to have children, discuss HCG or freeze sperm before starting TRT.
"HCG is a water-based peptide hormone that can be injected to replace the lost LH hormone that TRT shuts down. Without hCG, the LH receptors in the testes are no longer getting activated. The results: the testes shrink."
Reddit
Aromatization is the enzymatic conversion of testosterone to estrogen through the action of the aromatase enzyme. When estrogen levels rise excessively relative to testosterone, unwanted effects like gynecomastia can develop.
Serious Concerns: What the Research Actually Shows
Cardiovascular events sparked debate after a discontinued trial reported 23 events in the testosterone group versus 5 in placebo — a hazard ratio of 2.4.2 The participants were older men with multiple comorbidities, not typical TRT candidates. Critics pointed out the trial enrolled high-risk patients who shouldn't have started therapy.
Current consensus from the Endocrine Society: no strong evidence links TRT to increased cardiovascular mortality in properly selected patients.2 That means men without uncontrolled heart disease, recent stroke, or severe heart failure.
The FDA requires warnings about heart attack and stroke risks based on post-marketing reports. Seek immediate care if you experience chest pain, shortness of breath, or slurred speech.4
Prostate cancer fears are common but largely unfounded. PSA levels rise early on TRT because testosterone stimulates prostate tissue growth. A PSA increase is expected — it doesn't signal cancer progression.1
The Endocrine Society consensus: no evidence that TRT increases prostate cancer risk in men without active disease. Baseline PSA screening and annual monitoring catch any abnormal changes early. Men with a history of prostate or breast cancer should not use TRT.
Sleep apnea worsens in some men, particularly those who are obese. One study found oxygen desaturation events increased by 10.3 per hour at 7 weeks in men with severe apnea. The effect resolved by 18 weeks.2 If you have untreated sleep apnea, get it under control before starting TRT. CPAP therapy combined with weight loss mitigates the risk.
Erythrocytosis is an abnormal increase in red blood cell production that thickens the blood and elevates hematocrit levels. On TRT, elevated hematocrit above 54% increases the risk of stroke and blood clots if left untreated.
How Monitoring Prevents Most TRT Complications
Erythrocytosis — elevated red blood cell production — is the most common lab abnormality on TRT. Your body produces more red blood cells in response to testosterone, which thickens your blood. High hematocrit above 54% increases stroke and clot risk if left unchecked.
Your clinician checks hematocrit at baseline, 3-6 months, and annually. If your hematocrit exceeds 54%, you pause therapy until levels normalize.2 Therapeutic phlebotomy — a controlled blood donation — brings levels down quickly. Most men resume treatment at a lower dose without recurrence.
PSA monitoring starts at baseline and continues annually. An early rise is normal. A rapid spike or continued elevation above 4.0 ng/mL triggers further investigation. Most PSA changes on TRT reflect benign prostate growth, not cancer.
Sleep apnea screening matters if you're overweight or have a history of snoring. Untreated apnea worsens on TRT and compounds cardiovascular risk. A sleep study before starting therapy identifies cases that need CPAP first.
Fertility and testicular function require HCG if preservation matters. Standard TRT suppresses sperm production within weeks. Adding HCG from the start maintains fertility and prevents testicular atrophy.
Therapeutic Phlebotomy is a controlled blood donation procedure used to reduce elevated hematocrit and red blood cell levels. This intervention quickly normalizes blood thickness and stroke risk in patients on TRT.
Quick Reference: TRT Side Effect Severity and Monitoring
| Side Effect | Severity | Prevalence | Reversible? | Monitoring Needed |
|---|---|---|---|---|
| Acne / oily skin | Mild | Some men | Yes | Clinical observation |
| Gynecomastia | Moderate | Minority | Early stages | Physical exam, estradiol labs |
| Erythrocytosis (HCT >54%) | Serious if unmonitored | Common | Yes with phlebotomy | Hematocrit at baseline, 3-6 mo, annually |
| Fluid retention | Mild | Most men initially | Yes | Weight tracking, clinical observation |
| Reduced fertility / testicular shrinkage | Moderate | Universal without HCG | Yes after stopping TRT | Semen analysis if planning children |
| Sleep apnea worsening | Moderate to serious | Obese men at higher risk | Often self-resolves | Sleep study if symptomatic |
| PSA elevation | Mild (if no cancer) | Common | N/A | PSA at baseline, annually |
| Cardiovascular events | Serious | Rare in healthy men | Varies | Cardiovascular screening, lipid panel |
Most side effects are dose-dependent and reversible with protocol adjustments. The serious complications occur almost exclusively when baseline screening is skipped or monitoring lapses.
What to Expect: Timeline and When to Seek Help
Mild side effects like acne typically appear within 2-4 weeks as your testosterone levels stabilize. Most resolve within 2-3 months after a dose adjustment or formulation switch. Oily skin and fluid retention follow the same timeline.
Erythrocytosis develops gradually. Your hematocrit climbs over months, not days. Routine labs at 3-6 months catch elevated levels before symptoms appear. If you notice headaches, fatigue, or shortness of breath before your scheduled bloodwork, call your clinic.
PSA changes show up within the first few months. An early rise is expected. Your clinician tracks the rate of change — a slow, steady climb is normal, while a rapid spike triggers further evaluation.
Sleep apnea symptoms may worsen in the first 6-8 weeks if you're already at risk. Increased snoring, morning headaches, or daytime fatigue warrant a sleep study. The effect often resolves by 18 weeks as your body adjusts.2
Baseline screening before starting TRT catches conditions that contraindicate therapy. Your clinician checks your prostate and breast cancer status, sleep apnea history, and cardiovascular risk factors. Skipping this step increases your risk of serious complications.
Related Concerns: Fertility, Prostate Health, and Long-Term Safety
Fertility suppression is reversible but not immediate. Your sperm production drops within weeks of starting TRT and your testicles shrink. After stopping therapy, recovery takes 6-18 months — sometimes longer.3 If you're planning to have children, ask about HCG or sperm cryopreservation before your first injection.
Prostate cancer fears stem from outdated assumptions. The Endocrine Society consensus: no strong evidence links TRT to increased prostate cancer risk in properly screened men.2 A PSA rise on TRT is expected because testosterone stimulates prostate tissue. It's not cancer progression. Annual monitoring catches abnormal changes early.
Benign prostatic hyperplasia (BPH) may worsen on TRT in men who already have urinary symptoms. Testosterone stimulates prostate growth, which can increase urinary frequency or difficulty starting urination. Your clinician evaluates prostate size and urinary symptoms before starting therapy.
Long-term cardiovascular safety remains debated. Current evidence shows no significant risk in healthy men with proper monitoring. Low testosterone itself correlates with higher mortality — 17.2% versus 9% in men with normal levels.2 The key is excluding high-risk candidates and tracking cardiovascular markers throughout treatment.